# Provider Clinical Summary (PROVIDER-ONLY)

_Decision-support summary. Not a diagnosis, treatment recommendation, or dosing guidance._

**Patient:** James O'Brien (DEMO-005)
**Status:** active · **Risk level:** Critical Review Priority
**Latest assessment:** 2026-06-14T00:42:40.359003+00:00 · **Last follow-up:** 2026-03-07T09:00:00+00:00

## Clinical snapshot
- Primary phenotype: immune_dysregulation
- Secondary phenotype: mold_cirs_pattern
- Recovery stage (derived): improving — Clinical improvement score 56 (56–69 vs baseline).
- Confidence: 70 (moderate)
- Top contributors: Flushing / hives (mast cell activation), Chemical / scent sensitivity, New or worsening allergies, Recurrent infections, Swollen lymph nodes

## Co-infection pattern scores
- bartonella: 0
- babesia: 0
- ebv: 0
- mold_cirs: 17
- mcas: 89

## Lab system scores
- inflammatory: 0
- immune: 40
- mitochondrial: 0
- hormonal: 0
- metabolic: 0
- nutritional: 0
- detoxification: 0
- neuroinflammatory: 0
- connective_tissue: 0
- Abnormal: eosinophils (high)
- Missing: 42 marker(s)

## Safety review
- Overall: 88 (Critical Review Priority)
- Critical: reaction_history
- High: reaction_history, reaction_history
- Missing safety info: allergy_history_confirmed, pregnancy_status_confirmed, infection_status_confirmed

## Outcomes
- Clinical improvement score: 56
- Functional improvement score: 54

## Provider review
- Status: reviewed
- Notes: MCAS pattern with anaphylaxis history — START LOW. Reaction-risk is the gating consideration; engine flagged critical.

_Generated decision-support summary — physician review required. Source documents remain the source of truth._